Canaccord Genuity revised its price target for Cybin Inc. (NYSE:CYBN) shares, reducing it to $73.00 from the previous $86.00, ...
A local nature-based therapy company is offering monthly nature-connection sessions to improve people’s mental wellbeing, ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback